CN114702700B - 一种用于血液灌流器抗凝填料的制备方法 - Google Patents
一种用于血液灌流器抗凝填料的制备方法 Download PDFInfo
- Publication number
- CN114702700B CN114702700B CN202210501506.5A CN202210501506A CN114702700B CN 114702700 B CN114702700 B CN 114702700B CN 202210501506 A CN202210501506 A CN 202210501506A CN 114702700 B CN114702700 B CN 114702700B
- Authority
- CN
- China
- Prior art keywords
- solution
- reaction
- filler
- acrylamide
- lysine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000945 filler Substances 0.000 title claims abstract description 55
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 35
- 229940127219 anticoagulant drug Drugs 0.000 title claims abstract description 35
- 230000008081 blood perfusion Effects 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 239000002245 particle Substances 0.000 claims abstract description 66
- 229920005989 resin Polymers 0.000 claims abstract description 60
- 239000011347 resin Substances 0.000 claims abstract description 60
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000004472 Lysine Substances 0.000 claims abstract description 43
- 238000006243 chemical reaction Methods 0.000 claims description 52
- -1 2, 2-dimethoxy ethyl Chemical group 0.000 claims description 50
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- 238000001914 filtration Methods 0.000 claims description 35
- 238000005406 washing Methods 0.000 claims description 35
- 239000008367 deionised water Substances 0.000 claims description 34
- 229910021641 deionized water Inorganic materials 0.000 claims description 34
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
- 238000003756 stirring Methods 0.000 claims description 30
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 230000001951 hemoperfusion Effects 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 230000010355 oscillation Effects 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 13
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 11
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- 229920005990 polystyrene resin Polymers 0.000 claims description 9
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 230000035484 reaction time Effects 0.000 claims description 6
- XSHISXQEKIKSGC-UHFFFAOYSA-N 2-aminoethyl 2-methylprop-2-enoate;hydron;chloride Chemical compound Cl.CC(=C)C(=O)OCCN XSHISXQEKIKSGC-UHFFFAOYSA-N 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims 2
- 102000013566 Plasminogen Human genes 0.000 abstract description 12
- 108010051456 Plasminogen Proteins 0.000 abstract description 12
- 239000003463 adsorbent Substances 0.000 abstract description 10
- 230000010100 anticoagulation Effects 0.000 abstract description 8
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 239000011248 coating agent Substances 0.000 abstract description 7
- 238000000576 coating method Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 229940012957 plasmin Drugs 0.000 abstract description 6
- 208000007536 Thrombosis Diseases 0.000 abstract description 5
- 238000011049 filling Methods 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 230000002537 thrombolytic effect Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000000004 hemodynamic effect Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 64
- 238000004108 freeze drying Methods 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000007037 hydroformylation reaction Methods 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000001179 sorption measurement Methods 0.000 description 7
- 230000015271 coagulation Effects 0.000 description 6
- 238000005345 coagulation Methods 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- 230000020764 fibrinolysis Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 125000004036 acetal group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/12—Powdering or granulating
- C08J3/126—Polymer particles coated by polymer, e.g. core shell structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2325/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring; Derivatives of such polymers
- C08J2325/02—Homopolymers or copolymers of hydrocarbons
- C08J2325/04—Homopolymers or copolymers of styrene
- C08J2325/06—Polystyrene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2433/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
- C08J2433/24—Homopolymers or copolymers of amides or imides
- C08J2433/26—Homopolymers or copolymers of acrylamide or methacrylamide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
纤溶酶原吸附率(%) | 溶血率(%) | |
实施例1 | 60.5% | 2.1 |
实施例2 | 63.1% | 0.9 |
实施例3 | 61.9% | 1.5 |
实施例4 | 59.3% | 1.3 |
对比例1 | 28.4% | 4.7 |
对比例2 | 32.7% | 3.6 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210501506.5A CN114702700B (zh) | 2022-05-09 | 2022-05-09 | 一种用于血液灌流器抗凝填料的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210501506.5A CN114702700B (zh) | 2022-05-09 | 2022-05-09 | 一种用于血液灌流器抗凝填料的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114702700A CN114702700A (zh) | 2022-07-05 |
CN114702700B true CN114702700B (zh) | 2023-11-21 |
Family
ID=82175984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210501506.5A Active CN114702700B (zh) | 2022-05-09 | 2022-05-09 | 一种用于血液灌流器抗凝填料的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114702700B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005048061A (ja) * | 2003-07-29 | 2005-02-24 | Kohei Shiraishi | 抗血栓性に優れた高分子組成物及びそれからなる医療用材料 |
CN110950772A (zh) * | 2018-09-26 | 2020-04-03 | 天津大学 | N-(2,2-二甲氧基乙基)丙烯酰胺的制备方法及由其制备得到的醛基官能化共聚物 |
CN112473636A (zh) * | 2019-09-11 | 2021-03-12 | 云南师范大学 | 一种包膜并共价固定肝素的血液灌流吸附剂及其制备方法 |
CN113385151A (zh) * | 2021-05-27 | 2021-09-14 | 北京中科盛康科技有限公司 | 一种血液灌流器用树脂智能包膜工艺系统 |
-
2022
- 2022-05-09 CN CN202210501506.5A patent/CN114702700B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005048061A (ja) * | 2003-07-29 | 2005-02-24 | Kohei Shiraishi | 抗血栓性に優れた高分子組成物及びそれからなる医療用材料 |
CN110950772A (zh) * | 2018-09-26 | 2020-04-03 | 天津大学 | N-(2,2-二甲氧基乙基)丙烯酰胺的制备方法及由其制备得到的醛基官能化共聚物 |
CN112473636A (zh) * | 2019-09-11 | 2021-03-12 | 云南师范大学 | 一种包膜并共价固定肝素的血液灌流吸附剂及其制备方法 |
CN113385151A (zh) * | 2021-05-27 | 2021-09-14 | 北京中科盛康科技有限公司 | 一种血液灌流器用树脂智能包膜工艺系统 |
Non-Patent Citations (1)
Title |
---|
陆晓雯.多功能醋酸纤维素超细纤维膜的构筑及性能研究.2019,(01),第四章. * |
Also Published As
Publication number | Publication date |
---|---|
CN114702700A (zh) | 2022-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104174385B (zh) | 一种用于血液灌流的胆红素吸附剂 | |
CN109675134A (zh) | 一种血液透析器的抗凝改性方法及其应用 | |
CN112439397A (zh) | 一种包膜并固载肝素的血液灌流吸附剂及其制备方法 | |
Winchester et al. | Sorbent hemoperfusion in end-stage renal disease: an in-depth review | |
CN104147653A (zh) | 具有抗凝缓释功能的血液灌流器及其制备方法 | |
Liu et al. | Alginate/HSA double-sided functional PVDF multifunctional composite membrane for bilirubin removal | |
CN112871139A (zh) | 一种全血灌流吸附剂、其制备方法及应用 | |
CN111250055B (zh) | 基于壳聚糖的血液灌流吸附剂及其在制备用于脓毒血症血液净化的血液灌流器中的应用 | |
CN114702700B (zh) | 一种用于血液灌流器抗凝填料的制备方法 | |
CN113600148B (zh) | 基于肝素改性壳聚糖/纤维素微球的血液灌流吸附剂、其制备方法及其应用 | |
CN113385151A (zh) | 一种血液灌流器用树脂智能包膜工艺系统 | |
CN109692372A (zh) | 一种五层血液灌流器及血液灌流方法 | |
CN109734839A (zh) | 一种高抗凝型聚苯乙烯微球及其制备方法与应用 | |
CN114099763A (zh) | 一种钙离子交换多孔淀粉止血材料及其应用 | |
CN109794172A (zh) | 一种用于血液净化的抗菌中空纤维膜的制备方法 | |
US20070077555A1 (en) | Adsorption system for the removal of viruses and viral components from fluids, in particular blood and blood plasma | |
CN109248668A (zh) | 用于血液体外循环去除ldl的吸附剂及其制备方法和灌流器 | |
JPS5836624B2 (ja) | 血液処理用吸着剤 | |
CN108484947B (zh) | 一种低表面张力溶液制备仿生涂层的方法 | |
CN113509919A (zh) | 一种可用于清除脓毒症患者血液中内毒素和炎症因子的吸附剂及其制备方法 | |
JPS59186558A (ja) | リウマチ因子および/またはその免疫複合体の吸着材 | |
CN116492991B (zh) | 可清除血液中TNF-α的血液灌流器填料制备方法 | |
CN114699584B (zh) | 一种自抗凝双层多孔芳纶血液灌流器及其应用 | |
CN110624512A (zh) | 一种基于氧化石墨烯接枝脲酶的核壳结构类肝素微球及其制备方法和应用 | |
CN114042441A (zh) | 在血液灌流树脂微球表面修饰并固载肝素的方法及其制备的吸附剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220804 Address after: No. 89, Xicha Village, Xicha Town, Gaolan County, Lanzhou New District, Lanzhou City, Gansu Province 730300 Applicant after: Lu Xuefeng Address before: E303, e305, E307 and E309, Liye building, No. 20 Qingyuan Road, Xinwu District, Wuxi City, Jiangsu Province, 214000 Applicant before: Jiangsu Qirui Biotechnology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230609 Address after: E303, e305, E307 and E309, Liye building, No. 20 Qingyuan Road, Xinwu District, Wuxi City, Jiangsu Province, 214000 Applicant after: Jiangsu Qirui Biotechnology Co.,Ltd. Address before: No. 89, Xicha Village, Xicha Town, Gaolan County, Lanzhou New District, Lanzhou City, Gansu Province 730300 Applicant before: Lu Xuefeng |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |